In this article
Bariatric Surgery and Reduced Melanoma Risk
In addition to rapid and lasting weight loss and other health benefits, bariatric surgery is now associated with a 61% reduced risk of malignant melanoma, which is the deadliest skin cancer most closely associated with excessive sun exposure.
The new study will be released on Thursday at the European Obesity Conference in Vienna, Austria. The study also found that the risk of skin cancer in people undergoing bariatric surgery generally decreased by 42%. Among a group of 2,007 obese participants undergoing bariatric surgery in Sweden, the median follow-up period was 18 years.
Methodology and Control Group Comparison
In this study, subjects who chose surgery as an obesity treatment were compared with 2,040 obese Swedes. The control group had similar basic conditions as the surgical patients, including age, gender, height, cardiovascular risk factors, and psychological Social variables and personality traits, but no cuts.
A research team led by Magdalena Taube from the University of Gothenburg in Sweden believes that changing the risk of melanoma in subjects is deep weight loss. This finding supports the notion that obesity is a risk factor for melanoma, and shows that weight loss in obese patients can reduce the risk of increasing fatal cancer in many countries for decades.
The American Cancer Society estimates that in 2018, about 91,270 new melanomas will be diagnosed in the United States, with 55,150 males and 36,120 females. About 9,320 people will die from the disease. The organization also reported a recent increase in the incidence of melanoma: between 2008 and 2018, the number of new melanoma cases diagnosed each year increased by 53%.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Alysha Mendossa
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.